Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2007;335:464 (8 September), doi:10.1136/bmj.39325.444491.3A
| The first 150 words of the full text of this article appear below. |
Markus leaps from a discussion about outcomes to a plea to reorganise acute stroke care to improve access to thrombolysis.1 Not one patient received thrombolytic treatment in the studies he quotes, but such subtleties will be lost in the political hubbub about the NHS letting us all down yet again. It is frustrating that after 25 years' research, we have only one drug treatment, alteplase, which seems to work, and we only manage to give it to 2% of our patients, but we should not put all our eggs in this basket.
About 1 in 8 patients would expect to obtain major benefit from thrombolytic treatment, so even if we could increase the proportion treated to 20%, about 1 in 40 patients would benefit overall. To achieve this, Markus suggests that patients receive "rapid ambulance assessment" and perhaps half would be transferred to "specialised stroke centres," some distance away.1 What
David Barer, professor in stroke medicine
Queen Elizabeth Hospital, Gateshead, Tyne and Wear NE9 6SX
d.h.barer@ncl.ac.uk